ecNumber*3.4.21.68#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*29594#!ecNumber*3.4.21.68#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Mus musculus#literature*29597#!ecNumber*3.4.21.68#specificActivity*-999#specificActivityMaximum*#commentary*specific activity of 240000 I.U./mg protein#organism*Homo sapiens#literature*649779#!ecNumber*3.4.21.68#specificActivity*-999#specificActivityMaximum*#commentary*a study in sporadic Alzheimer's disease and age-matched control brain tissues reveals that the tPA proteolytic activity is negatively correlated to amyloid-beta peptide levels#organism*Homo sapiens#literature*683922#!ecNumber*3.4.21.68#specificActivity*-999#specificActivityMaximum*#commentary*cerebral tPA activity is decreased during ageing in normal mice and this effect is worsened in mice overproducing amyloid-beta peptide assemblies. These phenomena result from a decrease in tPA expression and from an increase in the production of one of the tPA inhibitors, the plasminogen activator inhibitor type 1 (PAI-1)#organism*Mus musculus#literature*683922#!ecNumber*3.4.21.68#specificActivity*-999#specificActivityMaximum*#commentary*the plasminogen activator inhibitor-1 antigen and its activity and their ratios to tissue-type plasminogen activator are all paradoxically lower with advancing age in patients with type 2 diabetes mellitus, t-PA is significantly and directly associated with increasing age#organism*Homo sapiens#literature*707027#!ecNumber*3.4.21.68#specificActivity*-999#specificActivityMaximum*#commentary*tPA and PAI-1 activities in neural cells, overview#organism*Rattus norvegicus#literature*718168#!ecNumber*3.4.21.68#specificActivity*0.297#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*29587#!ecNumber*3.4.21.68#specificActivity*7.4#specificActivityMaximum*#commentary*purified recombinant truncated enzyme, pH 8.3, 37&Acirc;&deg;C#organism*Homo sapiens#literature*717411#